A Selective RPL15 PROTAC Degrader Enhances Anti-PD-1 Immunotherapy in a Murine Melanoma Tumor Model

The authors synthesized SN-38-conjugated pomalidomide (SN38-PROTAC) and showed that SN38-PROTAC induced ubiquitin-mediated degradation of RPL15, but not topoisomerase I.